Difelikefalin: complete guide

Difelikefalin is a synthetic kappa opioid receptor agonist peptide first approved by FDA as Korsuva in 2021. This guide covers its structure, mechanism, labeled use, trials and warnings.

Complete guide6 min read

Key takeaway

FDA first approved difelikefalin as Korsuva on August 23, 2021. It is built from four D-amino acids and weighs 679.8 g/mol in PubChem. In the label’s two phase 3 trials, 40% and 37% of Korsuva patients had an itch drop of 4 points or more. On placebo, the figures were 21% and 26%.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Korsuva on August 23, 2021.” (this article)
ClassNeuropeptides
Body systemsBrain & nervous system
Studies cited2 in this article · 2 across 1 article on Difelikefalin
Related productsNeuropeptides

Difelikefalin is a small synthetic peptide that activates kappa opioid receptors. FDA approved it as Korsuva for itch linked to chronic kidney disease in adults on hemodialysis. This guide covers its structure, mechanism, approval, trials and label warnings, with sources checked on November 17, 2026.

Quick answer: Difelikefalin is a prescription peptide that acts on kappa opioid receptors. Its label covers moderate-to-severe itch from chronic kidney disease in adults undergoing hemodialysis. It has no boxed warning. Label warnings cover dizziness, sleepiness, mental status changes, gait problems and the risks of driving.

Vitrapep does not sell difelikefalin; this page is a reference summary of published research and regulatory information.

What is difelikefalin?

The Korsuva label describes difelikefalin as “a synthetic peptide with a single stereoisomer” that is present as an acetate salt (Korsuva label, 2025). In plain terms, it is a lab-made chain of amino acids, built in one fixed three-dimensional shape.

It counts as a peptide because its backbone is a short chain of four amino acids. PubChem’s structure shows two phenylalanines, a leucine and a lysine, all in the D form. A 4-aminopiperidine-4-carboxylic acid unit caps the chain. D-amino acids are mirror images of the L forms found in most natural proteins. PubChem lists the formula as C36H53N7O6 and the molecular weight as 679.8 g/mol (PubChem CID 24794466). Our guide to types of peptides explains where short synthetic peptides fit.

Drugs@FDA lists the original approval of Korsuva on August 23, 2021. The application is NDA 214916, now held by Vifor (International) (Drugs@FDA). The label names Vifor as the company that markets it.

Table 1

Difelikefalin: key facts

Fact Detail
Structure type Synthetic peptide of four D-amino acids with a piperidine cap
Class Kappa opioid receptor agonist
Molecular formula C36H53N7O6 (free base)
Molecular weight 679.8 g/mol
First FDA approval August 23, 2021 (Korsuva, NDA 214916)
Brand names (US) Korsuva

How does difelikefalin work?

The label is brief on mechanism. It states: “KORSUVA is a kappa opioid receptor (KOR) agonist.” It then adds: “The relevance of KOR activation to therapeutic effectiveness is not known” (Korsuva label, 2025).

An agonist is a molecule that switches a receptor on. The authors of the first phase 3 trial call difelikefalin “a peripherally restricted and selective agonist of kappa opioid receptors.” They add that these receptors are “considered to be important in modulating pruritus in conditions such as chronic kidney disease” (Fishbane et al., 2020). Peripherally restricted means it is meant to act mainly outside the brain and spinal cord. Our explainer on how peptides work covers receptor signaling in general.

What is difelikefalin approved for?

The Korsuva label has a single indication. It states that Korsuva “is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).” Pruritus is the medical word for itch.

The label also sets a limit. It says Korsuva “has not been studied in patients on peritoneal dialysis and is not recommended for use in this population” (Korsuva label, 2025).

What did the key trials show?

KALM-1. This human phase 3 trial was randomized, double-blind and placebo-controlled. It enrolled adults on hemodialysis with moderate-to-severe itch, and 378 patients underwent randomization. Its primary outcome was a decrease of at least 3 points on a worst-itch rating scale.

That outcome occurred in 82 of 158 patients (51.9%) on difelikefalin and 51 of 165 (30.9%) on placebo. Diarrhea, dizziness and vomiting were more common with difelikefalin. The authors concluded that patients on difelikefalin had “a significant reduction in itch intensity” and better itch-related quality of life (Fishbane et al., 2020). The registry record is NCT03422653.

KALM-2 and the label results. The second phase 3 trial was a global study with the same basic design (NCT03636269). The label reports a stricter end point from both trials. It is a drop of 4 points or more in the weekly worst-itch score at week 12. In Trial 1, 40% of Korsuva patients met it versus 21% on placebo. In Trial 2, the figures were 37% versus 26%.

A pooled analysis of both trials covered 851 randomized adults: 426 on difelikefalin and 425 on placebo. A drop of 3 points or more occurred in 51.1% with difelikefalin and 35.2% with placebo (Topf et al., 2022). All of these data come from human trials.

What side effects does the label list?

The Korsuva label has no boxed warning. Its safety data pool the two placebo-controlled phase 3 trials, with 424 patients on Korsuva and 424 on placebo. The label lists these adverse reactions as more common with Korsuva:

  • diarrhea (9.0% vs 5.7% on placebo);
  • dizziness (6.8% vs 3.8%);
  • nausea (6.6% vs 4.5%);
  • gait disturbances, including falls (6.6% vs 5.4%);
  • high blood potassium, or hyperkalemia (4.7% vs 3.5%);
  • headache (4.5% vs 2.6%);
  • sleepiness, or somnolence (4.2% vs 2.4%); and
  • mental status change (3.3% vs 1.4%).

The warnings section has two parts. The first covers dizziness, somnolence, mental status changes and gait disturbances. The second covers the risk of driving and operating machinery (Korsuva label, 2025).

What is difelikefalin’s regulatory status, and how is it used in research?

Korsuva is a prescription drug in the United States. Drugs@FDA lists its marketing status as prescription (Drugs@FDA). The DailyMed label lists its DEA controlled-substance status as “None.”

Researchers have also tested an investigational form of difelikefalin in another itch condition. Cara Therapeutics ran a phase 2/3 trial in notalgia paresthetica, a nerve-related itch of the upper back. The registry lists that trial as terminated. It explains that the investigational form “did not demonstrate a meaningful clinical benefit” compared with placebo in the trial’s first part (NCT05978063). That trial did not change the Korsuva indication.

Frequently asked questions about difelikefalin

Is difelikefalin a peptide?

Yes. The label calls it a synthetic peptide. It is a chain of four D-amino acids capped by a piperidine unit.

Is difelikefalin an opioid?

It acts on kappa opioid receptors, so it belongs to the opioid receptor agonist family. The DailyMed label lists its DEA controlled-substance status as “None.”

When was difelikefalin approved?

Drugs@FDA lists the original approval of Korsuva on August 23, 2021.

Is Korsuva approved for patients on peritoneal dialysis?

No. The label says it has not been studied in that group and is not recommended for it.

Does difelikefalin have a boxed warning?

No. Its label warnings cover dizziness, sleepiness, mental status changes, gait problems and the risks of driving or operating machinery.

What to know now

  • Structure: synthetic peptide of four D-amino acids; 679.8 g/mol.
  • Approval: Korsuva, August 23, 2021; prescription only.
  • Mechanism: kappa opioid receptor agonist, described by trialists as peripherally restricted.
  • Label: moderate-to-severe itch from chronic kidney disease in adults on hemodialysis.
  • Evidence: 51.9% vs 30.9% had a 3-point itch drop in KALM-1.
  • Safety: no boxed warning; diarrhea, dizziness and nausea lead the list.

What we’re watching

Further Korsuva label revisions on DailyMed, last revised in July 2025. Registry updates on difelikefalin trials in other itch conditions. Related guides: ziconotide and trofinetide.

More for brain & nervous system

All 12 compounds for brain & nervous system

Sources: Vifor (International) Inc 2025, KORSUVA (difelikefalin) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 214916 (KORSUVA) . Retrieved November 17, Drugs@FDA: NDA 214916 (KORSUVA); National Center for Biotechnology Information 2026, PubChem compound summary for CID 24794466, difelikefalin; Fishbane 2020, The New England Journal of Medicine, 382; Cara Therapeutics 2018; Cara Therapeutics 2018; Topf 2022, Kidney Medicine, 4; Cara Therapeutics 2023. All 8 citations

Back to the research library

References

  1. Vifor (International) Inc. (2025). KORSUVA (difelikefalin) prescribing information (revised 7/2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c7b81f2-0fd3-47cb-8b0f-185e07f19c87
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 214916 (KORSUVA). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214916
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 24794466, difelikefalin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/24794466
  4. Fishbane, S., et al. (2020). A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. The New England Journal of Medicine, 382(3), 222-232. https://doi.org/10.1056/NEJMoa1912770
  5. Cara Therapeutics, Inc. (2018). A study to evaluate the safety and efficacy of CR845 in hemodialysis patients with moderate-to-severe pruritus (KALM-1) (ClinicalTrials.gov ID NCT03422653). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03422653
  6. Cara Therapeutics, Inc. (2018). A global study to evaluate the safety and efficacy of CR845 in hemodialysis patients with moderate-to-severe pruritus (KALM-2) (ClinicalTrials.gov ID NCT03636269). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03636269
  7. Topf, J., Wooldridge, T., McCafferty, K., et al. (2022). Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: Pooled analysis of KALM-1 and KALM-2 phase 3 studies. Kidney Medicine, 4(8), 100512. https://doi.org/10.1016/j.xkme.2022.100512
  8. Cara Therapeutics, Inc. (2023). Study to evaluate the efficacy and safety of oral difelikefalin for moderate to severe pruritus in subjects with notalgia paresthetica (ClinicalTrials.gov ID NCT05978063). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05978063